

REGISTER OF INTERESTS

SIGN guideline: Update of SIGN 72: Cutaneous Melanoma

Published:

20 January 2017

	Financial		Non-financial		Non-personal	Date received at SIGN Executive	Action
	Specific	Non-Specific	Specific	Non-Specific			
CHAIR							
Ewan Brown, Consultant in Medical Oncology	Consultant in Medical Oncology, NHS Lothian.	None	Received funding to attend ASCO Oncology Conference – May 2014.	None	None	4.10.16	
GUIDELINE DEVELOPMENT GROUP MEMBER							
Stuart Ballantyne, Clinical Lead	Consultant Radiologist – NHS Greater Glasgow & Clyde & Golden Jubilee National Hospital.	None	None	None	None	5.10.16	
Richard Casasola, Consultant Clinical Oncologist	Consultant Clinical Oncologist, NHS Tayside	None	None	None	None	17.1.17	
Mark Darling, Consultant Dermatologist	Consultant Dermatologist, Skin and Cancer Foundation, Melbourne.	None	None	None	None	30.11.16	
Amanda Degabriele, MacMillan Skin Cancer Clinical Nurse Specialist	MacMillan Skin Cancer Specialist Nurse, NHS Tayside.	None	None	None	None	30.11.16	

REGISTER OF INTERESTS

SIGN guideline: Update of SIGN 72: Cutaneous Melanoma

Published:

20 January 2017

Robert Dickie, General Practitioner	Hospital Practitioner in Dermatology, NHS Western Isles. I undertake Dermatology clinics.	None	None	None	None	3.10.16	
Sheena Dryden, Clinical Nurse Specialist – Dermatology	Clinical Nurse Specialist – Skin Cancers, Lothian University Hospital Trust.	None	None	Secretary of British Association of Skin Cancer Nurses (group who consist primarily Sking Cancer Nurse Specialist). Working nationally to support Clinical Nurse Specialist for skin cancer nationally for promote/enhance good working practices and high levels of care with this group of patients.	None	29.11.16	
Elaine Fletcher, SpR, Clinical Genetics							
Susannah Fraser, Consultant	Consultant	None	None	None	None	29.11.16	

REGISTER OF INTERESTS

SIGN guideline: Update of SIGN 72: Cutaneous Melanoma

Published:

20 January 2017

Dermatologist	Dermatologist, NHS Fife & Spire Shawfair Park						
Alex Holme, Consultant and Training Programme Director	Consultant Dermatologist, NHS Lothian – Health care. Dr Alex Holme – private practice, Murrayfield Hospital, Edinburgh.	None	None	None	None	6.10.16	
Frances Kelly, Lay Representative	Catering Assistant, North Lanarkshire Council School	None	None	None	None	20.1.17	
Lucy Melly, Consultant Pathologist	Consultant Pathologist, Greater Glasgow and Clyde. Occasional work for 'Backlogs' – reporting cases from other NHS hospitals which have been sent to backlogs due to insufficient staffing levels at that hospital.	None	None	None	None	16.10.16	
Owen Moseley, Senior Health Economist	Senior Health Economist, Healthcare	None	None	None	None	29.11.16	

REGISTER OF INTERESTS

SIGN guideline: Update of SIGN 72: Cutaneous Melanoma

Published:

20 January 2017

	Improvement Scotland						
Colin Moyes, Consultant Dermatopathologist	<p>Consultant Pathologist, Greater Glasgow & Clyde.</p> <p>Consultant Pathologist, Ross Hall Hospital/Unilabs – self employed.</p> <p>Author in undergraduate textbook – Underwoods Pathology – royalties.</p>	None	None	None	None	28.11.16	
Omar Quaba, Consultant Plastic Surgeon	Consultant Plastic Surgeon, NHS Tayside	None	None	None	None	29.11.16	
Sanjay Rajpara, Consultant Dermatologist	<p>Consultant Dermatologist, NHS Grampian. BMI Albyn Hospital, Private Hospital.</p> <p>Director – Ace Dermatology Ltd – cosmetic dermatological treatments.</p>	None	None	None	None	12.10.16	
Alan Simms, Consultant	Consultant	None	None	None	None	29.11.16	

REGISTER OF INTERESTS

SIGN guideline: Update of SIGN 72: Cutaneous Melanoma

Published:

20 January 2017

Radiologist	Radiology, NHS Lothian						
Leigh Smith, Lay Representative	Volunteer Trustee, Chair MASScot, Melanoma Action and Support Scotland, SCI0040286 – charity objectives to support those diagnosed with skin cancer and their carers. Prevention education and campaigning on behalf of skin cancer patients. No members of the group. We do not have pharma members.	Shares & securities – No specific pharma or commercial shares, but have ISA funds managed by fund managers Ascentric on behalf of IFA. I have no active interest in these.	I attended a Post Chicago conference in Munich in 2015. I was sponsored by AIM at melanoma an American charity. Fares and hotel were paid by AIM. Being able to hear the lectures and the Q & As on the disease and a variety of new melanoma drugs was very valuable.	None	None	29.11.16	
Ashita Waterson, Consultant Medical Oncologist	Consultant Medical Oncologist, Greater Glasgow & Clyde Health Board.	None	None	None	Bristol Myers Squibb (BMS) – travel grant to attend ASCO 2015. MSD – travel grant to attend Society of	29.11.16	

REGISTER OF INTERESTS

SIGN guideline: Update of SIGN 72: Cutaneous Melanoma

Published:

20 January 2017

					Melanoma Research 2016. MSD – Fees for Acute Oncology immunotherapy talk. GSK, MSD and BMS – Involved in clinical trials within department.		
--	--	--	--	--	---	--	--